This study aimed to characterize the 24-month risk of cervical intraepithelial neoplasia grade ... of endocervical CIN 1 contributes to additional risk of high-grade CIN compared with women ...

Emily Fukuchi, MD; Barbara Fetterman, SCT (ASCP); Nancy Poitras, ACS, PMP; Walter Kinney, MD; Thomas Lorey, MD; Ramey D. Littell, MD To evaluate whether the presence of CIN 1 on ECC contributes to ...

The investigators assessed the efficacy of the vaccine against cervical intraepithelial neoplasia grade 2+ (CIN2+) lesions ... or a control vaccine at 0, 1 and 6 months; of these women, 92% ...

It was administered as two injections -- one intramuscular injection of 1 mL into each upper ... with HPV16-positive high-grade cervical intraepithelial neoplasia: a phase II trial" Clin Cancer ...

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade ... from 1.3%-30% within ...

Refika Yigit, MD, principal investigator and oncological gynecologist at University Medical Centre Groningen, Netherlands In those with grade 3 cervical intraepithelial neoplasia (CIN3), cells are ...

In those with grade 3 cervical intraepithelial neoplasia (CIN3), cells are already on the path toward malignancy. If left untreated, approximately one-third of these cases progress to cervical ...